Ganymed Pharmaceuticals

About:

Ganymed Pharmaceuticals is a biopharmaceutical developing therapeutic drugs designed to kill tumor cells without harming healthy tissues.

Website: http://www.ganymed.ag/

Top Investors: VI Partners, Nextech Invest, Landesbank Baden Wurttemberg, Future Capital, MIG Capital

Description:

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Total Funding Amount:

$213M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Mainz, Rheinland-Pfalz, Germany

Founded Date:

2001-01-01

Contact Email:

info(AT)ganymed.ag

Founders:

Christoph Huber, Dirk Sebastian

Number of Employees:

11-50

Last Funding Date:

2013-11-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai